Posted by Michael Wonder on 03 Jun 2024
Bavarian Nordic submits supplemental BLA seeking US FDA approval of freeze dried formulation of smallpox and mpox vaccine
31 May 2024 - Bavarian Nordic today announced the submission of a supplemental biologics license application to the US FDA seeking approval of a freeze dried formulation of Jynneos for prevention of smallpox and mpox disease in adults 18 years of age and older.
The liquid frozen formulation of Jynneos was approved by the FDA in September 2019.
